Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an ...

Competition is tightening, with Eli Lilly (NYSE:LLY) racing alongside Novo in the GLP-1 space. Novo's pipeline powerhouse, CagriSema, recently fell short of its weight-loss goals, but its established ...

Companies outside the U.S. often pursue a dual listing in New York to widen ... seek answers on Novo Nordisk's next-gen obesity drug CagriSema 6:23 AM UTC Diageo estimates its operating profit ...

The pressure on Novo Nordisk redoubled in December 2024. The results of a phase III clinical trial — an advanced stage of research — for its experimental drug CagriSema set off alarm bells: patients ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

Former Justice H S Bhalla has taken on the role of administrator for the Haryana Olympic Association, marking a significant transition for sports in the state. An HOA representative confirmed that ...

A big catalyst for the stock could come in June when the company is expected to provide more detailed clinical results for CagriSema, its next-generation weight loss drug. Investors were ...

Both Mounjaro and Zepbound include an ingredient called tirzepatide, which is a dual GIP and GLP-1 receptor ... on its next-generation obesity drug, CagriSema. Shares of NVO declined 4% on Tuesday ...

In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss treatment. Novo had set a target for patients to lose 25% of their body weight on average over 68 weeks.